 Connection
Bradley Corr to Poly(ADP-ribose) Polymerase Inhibitors
This is a "connection" page, showing publications Bradley Corr has written about Poly(ADP-ribose) Polymerase Inhibitors.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
1.716 |
|
|
|
-
Corr BR, Woodruff ER, Yamamoto TM, Jordan KR, Danhorn T, Bossard C, Nguyen LL, Chuong EB, Wick L, Young A, Kusumoto S, Orsulic S, Barroilhet L, Bitler BG. SM08502-Mediated ß-Catenin Repression Synergizes with Olaparib to Inhibit Tumor Progression. Cancer Res Commun. 2025 Dec 01; 5(12):2112-2126.
Score: 0.842
-
Corr BR, Haggerty A, Gysler SM, Taylor S, Behbakht K, Alldredge J, Lefkowits C, Brubaker LW, Bouts C, Babayan LM, Martin LP, Costello J, Bitler BG, Hu J, Guntupalli SR. A phase II, randomized, double-blind study of the use of rucaparib vs. placebo maintenance therapy in metastatic and recurrent endometrial cancer. Gynecol Oncol. 2025 Sep; 200:58-67.
Score: 0.821
-
Willman G, Podder V, Westin SN, Corr BR, Coleman RL, Pothuri B, Moore KN, Slomovitz BM. Homologous recombination deficiency in endometrial cancer: shedding light on recent clinical findings. Int J Gynecol Cancer. 2026 Feb; 36(2):102859.
Score: 0.053
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|